ATE406880T1 - Behandlung von motorischen veränderungen mit 5- hydrxoytryptamin 1a rezeptor aktivität verstärkenden wirkstoffen - Google Patents

Behandlung von motorischen veränderungen mit 5- hydrxoytryptamin 1a rezeptor aktivität verstärkenden wirkstoffen

Info

Publication number
ATE406880T1
ATE406880T1 AT01976536T AT01976536T ATE406880T1 AT E406880 T1 ATE406880 T1 AT E406880T1 AT 01976536 T AT01976536 T AT 01976536T AT 01976536 T AT01976536 T AT 01976536T AT E406880 T1 ATE406880 T1 AT E406880T1
Authority
AT
Austria
Prior art keywords
hydrxoytryptamine
actives
receptor activity
treatment
motor changes
Prior art date
Application number
AT01976536T
Other languages
English (en)
Inventor
Jonathan Brotchie
Michael Hill
Original Assignee
Motac Neuroscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9902589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE406880(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Motac Neuroscience Ltd filed Critical Motac Neuroscience Ltd
Application granted granted Critical
Publication of ATE406880T1 publication Critical patent/ATE406880T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Processing Of Meat And Fish (AREA)
  • Paper (AREA)
  • Threshing Machine Elements (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01976536T 2000-11-03 2001-10-29 Behandlung von motorischen veränderungen mit 5- hydrxoytryptamin 1a rezeptor aktivität verstärkenden wirkstoffen ATE406880T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0027020.7A GB0027020D0 (en) 2000-11-03 2000-11-03 Treatment of movement disorders

Publications (1)

Publication Number Publication Date
ATE406880T1 true ATE406880T1 (de) 2008-09-15

Family

ID=9902589

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01976536T ATE406880T1 (de) 2000-11-03 2001-10-29 Behandlung von motorischen veränderungen mit 5- hydrxoytryptamin 1a rezeptor aktivität verstärkenden wirkstoffen

Country Status (13)

Country Link
US (2) US20040067956A1 (de)
EP (1) EP1339398B1 (de)
JP (2) JP5189240B2 (de)
AT (1) ATE406880T1 (de)
AU (2) AU9580401A (de)
CA (1) CA2431641A1 (de)
CY (1) CY1108628T1 (de)
DE (1) DE60135675D1 (de)
DK (1) DK1339398T3 (de)
ES (1) ES2311549T3 (de)
GB (1) GB0027020D0 (de)
PT (1) PT1339398E (de)
WO (1) WO2002036107A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9924941D0 (en) * 1999-10-22 1999-12-22 Univ Manchester Treatment of dyskinesia
GB0027020D0 (en) 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
US9066903B2 (en) 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
RU2685718C2 (ru) * 2012-10-22 2019-04-23 Сивитас Терапьютикс, Инк. Лекарственные формы леводопы для быстрого купирования болезни паркинсона
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
JPWO2022045336A1 (de) * 2020-08-31 2022-03-03

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013766A1 (en) * 1992-01-07 1993-07-22 Merrell Dow Pharmaceuticals Inc. Treatment of involuntary movements with 5ht1a receptor agonists
EP0697894A4 (de) * 1993-03-31 1996-05-01 Univ Pennsylvania Dopamin d-3 und serotonin (5-ht 1a) rezeptor-liganden und bildgebunde mittel
GB9408084D0 (en) * 1994-04-23 1994-06-15 Boots Co Plc Medical treatment
GB9815618D0 (en) * 1998-07-18 1998-09-16 Univ Manchester Treatment of dyskinesia
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
US6136559A (en) 1998-10-07 2000-10-24 Ortho Pharmaceutical Corporation DNA encoding as human histamine receptor of the H3 subtype
GB9924941D0 (en) * 1999-10-22 1999-12-22 Univ Manchester Treatment of dyskinesia
GB0027020D0 (en) 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
CA2499200A1 (en) * 2002-09-17 2004-04-01 Motac Neuroscience Limited Use of compounds in the treatment of dyskinesia
US7786126B2 (en) * 2006-06-16 2010-08-31 Solvay Pharmaceuticals B.V. Combination preparations comprising SLV308 and a dopamine agonist
EP2035002A1 (de) 2006-06-16 2009-03-18 Solvay Pharmaceuticals B.V. Kombinationspräparate mit slv308 und einem l-dopa
AU2008330482A1 (en) 2007-11-30 2009-06-04 Daiichi Sankyo Company, Limited Agent for improving motor complications or psychiatric symptoms in Parkinson's disease

Also Published As

Publication number Publication date
DE60135675D1 (de) 2008-10-16
PT1339398E (pt) 2008-11-03
WO2002036107A3 (en) 2003-01-16
EP1339398B1 (de) 2008-09-03
US20040067956A1 (en) 2004-04-08
CY1108628T1 (el) 2014-04-09
US20110178178A1 (en) 2011-07-21
JP2004512360A (ja) 2004-04-22
JP2010241827A (ja) 2010-10-28
AU2001295804B2 (en) 2007-01-04
JP5189240B2 (ja) 2013-04-24
ES2311549T3 (es) 2009-02-16
US9668995B2 (en) 2017-06-06
WO2002036107A2 (en) 2002-05-10
DK1339398T3 (da) 2009-01-26
EP1339398A2 (de) 2003-09-03
GB0027020D0 (en) 2000-12-20
CA2431641A1 (en) 2002-05-10
AU9580401A (en) 2002-05-15

Similar Documents

Publication Publication Date Title
EA200301215A1 (ru) Лиганды рецепторов 5-ht и их применение
DK1337518T3 (da) Piperazinylpyrazinforbindelser som antagonister for serotonin-5-HT2-receptoren
FI954944A0 (fi) Indolijohdannaisia 5-HT1-kaltaisina agonisteina käytettäväksi migreenin hoitoon
DE60040981D1 (de) BEHANDLUNG MIT ANTI-ErbB2 ANTIKÖRPERN
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
DE60022692D1 (de) (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
AU5338301A (en) Methods and compositions for modulating alpha adrenergic receptor activity
DE60022226D1 (de) Benzimidazolverbindungen die nociceptinrezeptoraffinität haben
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
DK1225881T3 (da) Anvendelsen af dapoxetin, en hurtigt-virkende selektiv serotonin genoptagelseshæmmer, til behandling af seksuel dysfunktion
ATE357917T1 (de) Behandlung von dyskinesie durch mu-selektive opioidantagonisten
DE60035639D1 (de) Hydroxydiphenyletherverbindungen
SE9901077D0 (sv) Novel use
CY1108628T1 (el) Θεραπεια των κινητικων διακυμανσεων με ενωσεις ενισχυσης της δραστηριοτητας του υποδοχεα 5-υδροξυτρυπταμινη 1α
EA200301143A1 (ru) Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6
ATE253930T1 (de) Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)- aktivierungsweges
ATE460938T1 (de) Morpholin-derivate zur verwendung als dopaminagonisten in der behandlung von u.a. sexueller dysfunktion
ITRM990426A0 (it) Impiego di inibitori della sostanza p per il trattamento degli adenocarcinomi.
ATE333277T1 (de) Behandlung von dyskinesie
DK1438034T3 (da) Anvendelse af -phenyl-3-dimethylaminiopropanforbindelser til behandling af urininkontinens
ATE346040T1 (de) Aryl-sulfonamide als serotonin-antagonisten für de behandlung von fettleibigkeit
DK1161239T3 (da) 3- cyclopropylmethoxy-4-difluormethoxy-N-(3,5-dichlorpyrid-4-yl)benzamid til behandling af dissemineret sklerose
ATE345135T1 (de) Tropan-derivate mit dopamin-wiederaufnahme-hemmer-wirkung für die behandlung von ischämischen erkrankungen
ITMI982312A0 (it) Platorello o semiplatorello per macchine circolari monocilndriche per maglieria o calzetteria particolarmente per la produzione di
BR0314540A (pt) Métodos para o tratamento de neurodegeneração

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1339398

Country of ref document: EP